Skip to main content
. 2022 Apr 5;10(4):e004273. doi: 10.1136/jitc-2021-004273

Figure 3.

Figure 3

OS in patients randomized to (A) placebo, (B) nivolumab 240 mg Q2W, and (C) nivolumab 1 mg/kg plus ipilimumab 3 mg/kg Q2W with increases in target lesion SLD of <20% or ≥20% in CheckMate 451. OS, overall survival; Q2W, every 2 weeks; SLD, sum of the longest diameters.